What became of the aHUS 130?
Article No. 446 14 July 2021 Eculizumab effectiveness and safety in the treatment of aHUS was established in five clinical trials…
Article No. 446 14 July 2021 Eculizumab effectiveness and safety in the treatment of aHUS was established in five clinical trials…
Article No. 423 16 March 2021 Update: Seven days after this news blog was published a further report on the ravulizumab…
Break down in communication flows and fragmented outreach have built barriers for research and clinical trial enrollment regarding advancing new options for those with the rare disease atypical HUS (aHUS, or hemolytic uremic syndrome). The aHUS Alliance looks at current challenges, and potential pathways to explore and engage.
aHUS and TMA Study Centers An International List Compiled by the aHUS Alliance Atypical HUS is difficult…
The aHUS Alliance recently conducted an interview with Dr Ralf Reski, a professor and researcher in the field of…
An update on STOPECU ( NCT02574403) -the French Study of the withdrawal from eculizumab treatment which began in late 2015. ( click…
4 MYTHS of Rare Disease Advocacy: Digging deeper into Common Misperceptions Pathways of Patient Engagement & Recruitment…
From its beginning the aHUS alliance’s website has featured articles about the aHUS Registry and the work it does (click here…
Patients both desire and need to be involved at every level of their healthcare. Within the last decade there’s…